Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

Nature Medicine

Volumn 21, Issue 10, 2015, Pages 1154-1162

  Min, Sang Won ^a,b   Chen, Xu ^a,b   Tracy, Tara E ^a,b   Li, Yaqiao ^a   Zhou, Yungui ^a   Wang, Chao ^a,b   Shirakawa, Kotaro ^a   Minami, S Sakura ^a,b   Defensor, Erwin ^c   Mok, Sue Ann ^d   Sohn, Peter Dongmin ^a,d   Schilling, Birgit ^e   Cong, Xin ^e   Ellerby, Lisa ^e   Gibson, Bradford W ^e   Johnson, Jeffrey ^f   Krogan, Nevan ^f   Shamloo, Mehrdad ^c   Gestwicki, Jason ^d   Masliah, Eliezer ^g   Verdin, Eric ^a   Gan, Li ^a,b,d   more..

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^f GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; SALICYLIC ACID; SALSALATE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; ENZYME ACTIVITY; FRONTOTEMPORAL DEMENTIA; HUMAN; IN VIVO STUDY; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; TAUOPATHY; ACETYLATION; ANIMAL; ANIMAL BEHAVIOR; DEGENERATIVE DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETYLATION; ANIMALS; BEHAVIOR, ANIMAL; COGNITION DISORDERS; HUMANS; MICE; NEURODEGENERATIVE DISEASES; TAU PROTEINS;

EID: 84943637753     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3951     Document Type: Article

References (59)

1. Ludolph, A. C. et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 16, 297-309 (2009).
2. Cairns, N. J. et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 114, 5-22 (2007).
3. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).
4. Lasagna-Reeves, C. A. et al. Identification of oligomers at early stages of tau aggregation in Alzheimers disease. FASEB J. 26, 1946-1959 (2012).
5. Ren, Y. & Sahara, N. Characteristics of tau oligomers. Frontiers Neurol. 4, 102 (2013).
6. Maeda, S. et al. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimers disease. Neurosci. Res. 54, 197-201 (2006).
7. Lasagna-Reeves, C. A. et al. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener. 6, 39 (2011).
8. Berger, Z. et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662 (2007).
9. Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
10. Sydow, A. et al. Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model. J. Mol. Neurosci. 45, 432-437 (2011).
11. Wang, Y. & Mandelkow, E. Degradation of tau protein by autophagy and proteasomal pathways. Biochem. Soc. Trans. 40, 644-652 (2012).
12. Lee, B. H. et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184 (2010).
13. Tai, H. C. et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol. 181, 1426-1435 (2012).
14. Min, S. W. et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-966 (2010).
15. Cohen, T. J. et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 (2011).
16. Kim, G. W. & Yang, X. J. Comprehensive lysine acetylomes emerging from bacteria to humans. Trends Biochem. Sci. 36, 211-220 (2011).
17. Mandelkow, E. M. & Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2, a006247 (2012).
18. Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104-116 (2014).
19. Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351 (2007).
20. Jicha, G. A. , Bowser, R. , Kazam, I. G. & Davies, P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128-132 (1997).
21. Weaver, C. L. , Espinoza, M. , Kress, Y. & Davies, P. Conformational change as one of the earliest alterations of tau in Alzheimers disease. Neurobiol. Aging 21, 719-727 (2000).
22. Yeung, F. et al. Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD-dependent deacetylases. Oncogene 34, 798-804 (2015).
23. Wang, B. et al. Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nat. Commun. 5, 3479 (2014).
24. Zhao, Y. et al. p300-dependent acetylation of activating transcription factor 5 enhances C/EBPβ transactivation of C/EBPα during 3T3-L1 differentiation. Mol. Cell. Biol. 34, 315-324 (2014).
25. Jaworski, T. et al. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS ONE 4, e7280 (2009).
26. Lecourtier, L. et al. Intact neurobehavioral development and dramatic impairments of procedural-like memory following neonatal ventral hippocampal lesion in rats. Neuroscience 207, 110-123 (2012).
27. Takeuchi, H. et al. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS ONE 6, e21050 (2011).
28. Kasper, L. H. et al. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. EMBO J. 29, 3660-3672 (2010).
29. Kasper, L. H. , Qu, C. , Obenauer, J. C. , McGoldrick, D. J. & Brindle, P. K. Genome-wide and single-cell analyses reveal a context dependent relationship between CBP recruitment and gene expression. Nucleic Acids Res. 42, 11363-11382 (2014).
30. Jin, Q. et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 30, 249-262 (2011).
31. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
32. Yoshiyama, Y. , Kojima, A. , Ishikawa, C. & Arai, K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J. Alzheimers Dis. 22, 295-306 (2010).
33. Faizi, M. et al. Thy1-hAPPLond/Swe+ mouse model of Alzheimers disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2, 142-154 (2012).
34. Grinberg, L. T. et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 125, 581-593 (2013).
35. Irwin, D. J. et al. Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am. J. Pathol. 183, 344-351 (2013).
36. Irwin, D. J. et al. Acetylated tau, a novel pathological signature in Alzheimers disease and other tauopathies. Brain 135, 807-818 (2012).
37. Morris, M. et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18, 1183-1189 (2015).
38. Smith, W. L. , DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182 (2000).
39. in t Veld, B. A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimers disease. N. Engl. J. Med. 345, 1515-1521 (2001).
40. Aubry, S. et al. Assembly and interrogation of Alzheimers disease genetic networks reveal novel regulators of progression. PLoS ONE 10, e0120352 (2015).
41. Hawley, S. A. et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336, 918-922 (2012).
42. Zhang, Y. , Qiu, J. , Wang, X. , Zhang, Y. & Xia, M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol. 31, 2897-2908 (2011).
43. Lim, J. Y. , Oh, M. A. , Kim, W. H. , Sohn, H. Y. & Park, S. I. AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J. Cell. Physiol. 227, 1081-1089 (2012).
44. Greene, W. C. & Chen, L. F. Regulation of NF-κB action by reversible acetylation. Novartis Found. Symp. 259, 208-217 discussion 218-225 (2004).
45. Lee, H. et al. Ethanol selectively modulates inflammatory activation signaling of brain microglia. J. Neuroimmunol. 156, 88-95 (2004).
46. Apostolova, L. G. et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch. Neurol. 63, 693-699 (2006).
47. Kerchner, G. A. et al. Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology 75, 1381-1387 (2010).
48. Leung, K. K. et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology 80, 648-654 (2013).
49. Reagan-Shaw, S. , Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008).
50. Schilling, B. et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol. Cell. Proteomics 11, 202-214 (2012).
51. Shilov, I. V. et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 6, 1638-1655 (2007).
52. Perkins, D. N. , Pappin, D. J. , Creasy, D. M. & Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567 (1999).
53. Pagans, S. et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol. 3, e41 (2005).
54. Chen, J. et al. SIRT1 Protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J. Biol. Chem. 280, 40364-40374 (2005).
55. Barghorn, S. et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39, 11714-11721 (2000).
56. Moore, C. L. et al. Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation. Biochemistry 50, 10876-10886 (2011).
57. Winsor, C. P. The Gompertz curve as a growth curve. Proc. Natl. Acad. Sci. USA 18, 1-8 (1932).
58. Sun, A. , Nguyen, X. V. & Bing, G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 50, 463-472 (2002).
59. Kim, S. W. et al. Robust protective effects of a novel multimodal neuroprotectant oxopropanoyloxy benzoic acid (a salicylic acid/pyruvate ester) in the postischemic brain. Mol. Pharmacol. 79, 220-228 (2011).